Actively Recruiting
Real-World Study of Immunosuppressive Treatments for Adults With Non-Thymoma Ocular Myasthenia Gravis
Led by Tang-Du Hospital · Updated on 2026-01-30
200
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying new-onset ocular myasthenia gravis OMG, a condition affecting eye muscles, to collect clinical data and evaluate how different immunosuppressive treatments affect patient outcomes and side effects. The study also aims to identify factors that may increase the risk of OMG progressing to generalized myasthenia gravis GMG. This observational study takes place in multiple hospitals across China and involves patients diagnosed with ocular MG without thymoma. Treatment decisions, including symptomatic relief, steroids, and immunosuppressive drugs like azathioprine, tacrolimus, or mycophenolate mofetil, are made by physicians and patients based on medical judgment and preferences. Patients who agree to join the study are followed over time with regular assessments. Blood samples are collected annually, and clinical data such as chest imaging and antibody tests are recorded. The study plans to include 200 participants. Participants will be monitored regularly for changes in symptoms, treatment effects, and side effects using various scales and tests like the MG Status and Treatment Intensity scale, Quantitative Myasthenia Gravis scale, and antibody levels. Follow-up visits assess progression from ocular to generalized MG and relapse rates. The entire study follows patients up to about 144 weeks nearly three years, ensuring comprehensive tracking of disease status and treatment impact.
CONDITIONS
Brief Title
TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
Research Team
J
Jun Guo, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here